Tirzepatide (Mounjaro) reduces HbA1c by an average of 2.0% — outperforming every other approved GLP-1 class agent. This guide covers the diabetes-specific research protocol and SURPASS trial data.
Tirzepatide activates both GLP-1 and GIP receptors simultaneously. GLP-1 receptor agonism stimulates glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying — reducing both fasting and post-meal glucose. GIP receptor agonism provides additive insulin secretion from beta cells and improves insulin sensitivity in adipose tissue. The combination produces greater HbA1c reduction than GLP-1 agonism alone, as demonstrated in SURPASS-2 where tirzepatide outperformed semaglutide 1 mg at all doses. Both mechanisms are glucose-dependent, maintaining a low hypoglycemia risk profile.
| Compound | Mechanism | HbA1c | Weight | CV Data |
|---|---|---|---|---|
| Tirzepatide (Mounjaro) | Dual GLP-1/GIP | −2.0% | −8.5 kg | Yes (SURPASS-CVOT) |
| Semaglutide (Ozempic) | GLP-1 agonist | −1.5% | −4.5 kg | Yes (SUSTAIN-6) |
| Liraglutide (Victoza) | GLP-1 agonist | −1.2% | −3.0 kg | Yes (LEADER) |
| Metformin | AMPK activation | −1.0% | Neutral | Limited |
Yes. Tirzepatide (Mounjaro) received FDA approval for type 2 diabetes in May 2022. It is the first dual GLP-1/GIP receptor agonist approved for diabetes management. SURPASS-2 showed it outperforms semaglutide on HbA1c reduction at equivalent doses.
SURPASS trials show tirzepatide reduces HbA1c by an average of 2.0% at the 15 mg dose — the largest reduction of any approved GLP-1 class agent. At 5 mg and 10 mg doses, reductions average 1.6% and 1.9% respectively. This compares to approximately 1.5% for semaglutide.
SURPASS-2 directly compared tirzepatide to semaglutide 1 mg in type 2 diabetes. Tirzepatide at all doses (5, 10, 15 mg) produced greater HbA1c reduction and weight loss than semaglutide 1 mg. The dual GLP-1/GIP mechanism provides additive insulin sensitization that semaglutide's GLP-1-only mechanism does not.
FDA-approved Mounjaro dosing starts at 2.5 mg/week for 4 weeks, then 5 mg/week. The dose can be increased by 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg/week. Research protocols vary from this clinical dosing schedule.
Tirzepatide alone has a low risk of hypoglycemia because its insulin-stimulating effect is glucose-dependent — it only activates when blood glucose is elevated. The risk increases significantly when combined with sulfonylureas or insulin. In SURPASS trials, hypoglycemia rates were low when tirzepatide was used as monotherapy or with metformin.
GIP (glucose-dependent insulinotropic polypeptide) receptor agonism enhances insulin secretion from beta cells and may improve beta cell function and survival. GIP also acts on adipose tissue to improve insulin sensitivity. The combination of GLP-1 and GIP agonism produces greater HbA1c reduction than GLP-1 agonism alone, as demonstrated in the SURPASS-2 head-to-head trial.
Purgo Labs provides pharmaceutical-grade tirzepatide with third-party COAs. Use code HEALTH for 15% off.
Buy Tirzepatide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.